Mylan Asks Fed. Circ. To Undo PTAB Loss In Tecfidera Fight
Mylan Pharmaceuticals Inc. is urging the Federal Circuit to revive its challenge of a Biogen patent covering the blockbuster multiple sclerosis drug Tecfidera, saying that the Patent Trial and Appeal Board...To view the full article, register now.
Already a subscriber? Click here to view full article